Related Experiment Video

Updated: Aug 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting ErbB receptor signaling: a pan-ErbB approach to cancer

Carolyn D Britten1

  • 1Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA. cbritten@mednet.ucla.edu

Molecular Cancer Therapeutics
|October 16, 2004
PubMed

Insights

Targeting multiple ErbB receptors simultaneously may improve cancer therapy. This review explores strategies for concurrently inhibiting these key signaling proteins to overcome treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • ErbB receptors are key regulators of cell growth and survival.
  • Dysregulated ErbB signaling drives cancer progression and metastasis.
  • Current therapies target individual ErbB receptors with limited efficacy.

Purpose of the Study:

  • To review emerging strategies for concurrently inhibiting multiple ErbB receptors.
  • To highlight the therapeutic potential of multi-targeting ErbB-directed therapies.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of signaling pathways involving ErbB receptor cooperation.
  • Evaluation of therapeutic approaches targeting multiple ErbB receptors.

Main Results:

  • ErbB receptor family members exhibit cooperative signaling in cancer.
  • Concurrent inhibition of multiple ErbB receptors shows promise in preclinical models.
  • Development of novel agents targeting multiple ErbB receptors is ongoing.

Conclusions:

  • Simultaneous inhibition of multiple ErbB receptors represents a promising therapeutic strategy.
  • Overcoming resistance to ErbB-targeted therapies may be achieved through multi-targeting approaches.
  • Further research is needed to optimize combination therapies involving multiple ErbB inhibitors.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...